Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60 Read more about Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
Amgen Announces Webcast of 2013 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2013 Fourth Quarter and Full Year Financial Results
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol Read more about Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol
Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease Read more about Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference Read more about Amgen To Present At The 32nd Annual J.P. Morgan Healthcare Conference
Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer Read more about Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Appoints Michael A. Kelly Acting Chief Financial Officer
Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip Read more about Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol Read more about Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol Read more about Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
Amgen Announces 2014 First Quarter Dividend Read more about Amgen Announces 2014 First Quarter Dividend
